We are a regional leader, and a global partner.
Polpharma Group sells directly in 14 markets across Europe and Central Asia, distributes through partners in 40+ markets, and licenses finished dosage forms and APIs into more than 100.
Markets directly
12
Markets parntered
40+
Markets licensed
100+
Deals closed annually
60+
Global partners
600+
Revenue th. partners
20%
Direct presence
Distribution
API supply
FDF out-licensing
Presence
Own affiliates in core markets, partners and licensees beyond them.
Over 20% of Group revenue already flows through long-term partners. The models combine - in-licensing for B2C and pan-European out-licensing through B2B.
direct presence
Own commercial teams
Polpharma’s sales, marketing and medical teams manage customer relationships directly in core and adjacent markets.
distribution
Local distribution partners
Local distributors handle commercial execution, while Polpharma retains regulatory ownership and quality standards.
api supply
Global active ingredients supply
APIs produced in Europe since 1951 are supplied to pharmaceutical manufacturers worldwide.
FDF out-licensing
Out-licensing & global market entry
Finished-dosage products are licensed to established partners who register and sell them under their own brands.
Leading our home markets, and outgrowing them.
where we lead
Polpharma Group is among the 20 largest manufacturers of generic medicines worldwide.
Rx & CHC in PL & KZ
(relevant market)
Rx CAGR in PL 2021–25
vs 5.3% market
Revenue growth vs the market - CAGR 2021 - 2025 (%)
Entering Europe
Entry into Europe under our rights, or under yours, with our B2B unit as an agent.
Net sales by region
2025 · share of net sales
Net sales by channel
2025 · share of net sales
Operating geographies
From core manufacturing hubs to international market access.
Polpharma Group is built around two core pharmaceutical hubs in Poland and Kazakhstan, complemented by European commercial companies that extend the Group’s market and B2B reach.
A leading pharmaceutical base in Central and Eastern Europe.
Poland is the Group’s largest operating market, combining pharmaceutical manufacturing with a broad commercial organisation. From here, Polpharma serves the domestic market and supports operations across Central and Eastern Europe.
A major manufacturing and commercial hub for Central Asia.
Santo combines local pharmaceutical manufacturing with a strong market presence in Kazakhstan. Its operations also support the Group’s reach across neighbouring Central Asian markets.
Scalable Tender Platform in Europe's Largest Pharma Market
089PHARM develops opportunities in Germany through a tender-focused business model and retail market launches. The Munich-based team combines local market expertise, analytical capabilities and selected partnerships.
Extending the Group’s reach through B2B partnerships.
From Barcelona, Farmaprojects works with pharmaceutical partners across international markets, combining commercial expertise with regulatory capabilities and a broad portfolio of products and registrations.
Specialist coverage
Sold in forty countries, close to the specialists who prescribe.
Anchored in Poland and Kazakhstan, and across CEE, the CIS and South-East Asia. In the core markets, the field force reaches a large majority of specialists directly.
Balance & resilience
Diversified across regions and channels
Full pan-EU rights
Agency model
Market access & regulatory
Supply chain & logistics
Commercial coverage
R&D & manufacturing
Expansion · in execution
Building new market access from the Caucasus to the United States.
Active expansion programs are already underway across selected markets, combining distribution, out-licensing and direct B2B development.
EU GMP unlock
Caucasus & adjacent
EU GMP certification in Shymkent opens selected Caucasus and neighbouring markets to products manufactured in Kazakhstan, with entry pursued through local distribution and out-licensing partners.
EU GMP unlock
MENA & Southeast Asia
Polpharma is developing market-by-market partnerships across the Middle East, North Africa and Southeast Asia, using its EU GMP manufacturing base to support distribution and out-licensing opportunities.
B2B expansion
United States of America
Our B2B unit, Farmaprojects extends its regional BD model into the US - carried by the Group's hard-to-make and complex generic portfolio.
Supply chain expansion
India representative office
The Mumbai office strengthens Polpharma’s access to Indian API manufacturers and development partners, supporting sourcing, supply-chain resilience and new co-development opportunities.
partner with US
Enter, scale or supply a market
through the integrated pharmaceutical platform.
“Polpharma Group enables partners to succeed.”